Advances in kinase inhibition: Treating rheumatic diseases and beyond

Current Opinion in Rheumatology

Volumn 26, Issue 2, 2014, Pages 237-243

  Gadina, Massimo ^a  

^a NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

Author keywords

cytokines; jak; kinase; therapy

Indexed keywords

AUTOIMMUNE DISEASES; CYTOKINES; HUMANS; JANUS KINASES; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; RHEUMATIC DISEASES; SIGNAL TRANSDUCTION;

EID: 84894032258     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000023     Document Type: Review

References (47)

1. Scott DL. Biologics-based therapy for the treatment of rheumatoid arthritis. Clin Pharmacol Ther 2012; 91:30-43
2. Kontzias A, Laurence A, Gadina M, O'Shea JJ. Kinase inhibitors in the treatment of immune-mediated disease. F1000 Med Rep 2012; 4:5
3. O'Shea JJ, Murray PJ. Cytokine signaling modules in inflammatory responses. Immunity 2008; 28:477-487
4. Fischer EH. Cellular regulation by protein phosphorylation. Biochem Biophys Res Commun 2013; 430:865-867
5. Capdeville R, Buchdunger E, Zimmermann J, Matter A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 2002; 1:493-502
6. Hammaker D, Firestein GS. Go upstream, young man': Lessons learned from the p38 saga. Ann Rheum Dis 2010; 69 (Suppl 1):i77-i82
7. Nijjar JS, Tindell A, McInnes IB, Siebert S. Inhibition of spleen tyrosine kinase in the treatment of rheumatoid arthritis. Rheumatology 2013; 52:1556-1562
8. Salgado E, Maneiro JR, Carmona L, Gomez-Reino JJ. Safety profile of protein kinase inhibitors in rheumatoid arthritis: Systematic review and meta-Analysis. Ann Rheum Dis 2013; 0:1-12. doi:10.1136/annrheumdis-2012-203116
9. Mocsai A, Ruland J, Tybulewicz VL. The SYK tyrosine kinase: A crucial player in diverse biological functions. Nat Rev Immunol 2010; 10:387-402
10. O'Shea JJ, Kontzias A, Yamaoka K, et al. Janus kinase inhibitors in autoimmune diseases. Ann Rheum Dis 2013; 72 (Suppl 2):ii111-ii115
11. Russell SM, Tayebi N, Nakajima H, et al. Mutation of Jak3 in a patient with SCID: Essential role of Jak3 in lymphoid development. Science 1995; 270:797-800
12. LaBranche TP, Jesson MI, Radi ZA, et al. JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production. Arthritis Rheum 2012; 64:3531-3542
13. Ghoreschi K, Jesson MI, Li X, et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol 2011; 186:4234-4243
14. Kubo S, Yamaoka K, Kondo M, et al. The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells. Ann Rheum Dis 2013. doi: 10.1136/annrheumdis-2013-203756
15. Heine A, Held SA, Daecke SN, et al. The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo. Blood 2013; 122:1192-1202
16. Huang G, Wang Y, Vogel P, et al. Signaling via the kinase p38alpha programs dendritic cells to drive TH17 differentiation and autoimmune inflammation. Nat Immunol 2012; 13:152-161
17. Sohn SJ, Barrett K, Van Abbema A, et al. A restricted role for TYK2 catalytic activity in human cytokine responses revealed by novel TYK2-selective inhibitors. J Immunol 2013; 191:2205-2216
18. Famenini S, Wu JJ. The efficacy of ustekinumab in psoriasis. J Drugs Dermatol 2013; 12:317-320
19. Lowenberg M, D'Haens G. Novel targets for inflammatory bowel disease therapeutics. Curr Gastroenterol Rep 2013; 15:311
20. Van Rompaey L, Galien R, van der Aar EM, et al. Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases. J Immunol 2013; 191:3568-3577
21. Yokoyama S, Perera PY, Waldmann TA, et al. Tofacitinib a janus kinase inhibitor demonstrates efficacy in an IL-15 transgenic mouse model that recapitulates pathologic manifestations of celiac disease. J Clin Immunol 2013; 33:586-594
22. Lynch SM, DeVicente J, Hermann JC, et al. Strategic use of conformational bias and structure based design to identify potent JAK3 inhibitors with improved selectivity against the JAK family and the kinome. Bioorg Med Chem Lett 2013; 23:2793-2800
23. Jaime-Figueroa S, De Vicente J, Hermann J, et al. Discovery of a series of novel 5H-pyrrolo[2,3-b]pyrazine-2-phenyl ethers, as potent JAK3 kinase inhibitors. Bioorg Med Chem Lett 2013; 23:2522-2526
24. Soth M, Hermann JC, Yee C, et al. 3-Amido pyrrolopyrazine JAK kinase inhibitors: Development of a JAK3 vs. JAK1 selective inhibitor and evaluation in cellular and in vivo models. J Med Chem 2013; 56:345-356
25. Van Epps S, Fiamengo B, Edmunds J, et al. Design and synthesis of tricyclic cores for kinase inhibition. Bioorg Med Chem Lett 2013; 23:693-698
26. Labadie S, Barrett K, Blair WS, et al. Design and evaluation of novel 8-oxopyridopyrimidine Jak1/2 inhibitors. Bioorg Med Chem Lett 2013; 23:5923-5930
27. Liang J, Tsui V, Van Abbema A, et al. Lead identification of novel and selective TYK2 inhibitors. Eur J Med Chem 2013; 67:175-187
28. Liang J, van Abbema A, BalazsM, et al. Lead optimization of a 4-Aminopyridine benzamide scaffold to identify potent, selective, and orally bioavailable TYK2 inhibitors. 2013; J Med Chem:2013; 56:4521-4536
29. Zak M, Hurley CA, Ward SI, et al. Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2. J Med Chem 2013; 56:4764-4785
30. Chang BY, Huang MM, Francesco M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells. Arthr Res Ther 2011; 13:R1155
31. Di Paolo JA, Huang T, Balazs M, et al. Specific Btk inhibition suppresses B cell-And myeloid cell-mediated arthritis. Nat Chem Biol 2011; 7:41-50
32. Liu L, Di Paolo J, Barbosa J, et al. Antiarthritis effect of a novel Bruton's tyrosine kinase (BTK) inhibitor in rat collagen-induced arthritis and mechanism-based pharmacokinetic/pharmacodynamic modeling: Relationships between inhibition of BTK phosphorylation and efficacy. J Pharmacol Exp Ther 2011; 338:154-163
33. Biswas PS, Gupta S, Chang E, et al. Phosphorylation of IRF4 by ROCK2 regulates IL-17 and IL-21 production and the development of autoimmunity in mice. J Clin Investig 2010; 120:3280-3295
34. Stirzaker RA, Biswas PS, Gupta S, et al. Administration of fasudil, a ROCK inhibitor, attenuates disease in lupus-prone NZB/W F1 female mice. Lupus 2012; 21:656-661
35. Kovarik P, Mangold M, Ramsauer K, et al. Specificity of signaling by STAT1 depends on SH2 and C-Terminal domains that regulate Ser727 phosphorylation, differentially affecting specific target gene expression. EMBO J 2001; 20:91-100
36. Morinobu A, Gadina M, Strober W, et al. STAT4 serine phosphorylation is critical for IL-12-induced IFN-gamma production but not for cell proliferation. Proc Natl Acad Sci U S A 2002; 99:12281-12286
37. Shen Y, Schlessinger K, Zhu X, et al. Essential role of STAT3 in postnatal survival and growth revealed by mice lacking STAT3 serine 727 phosphorylation. Molec Cell Biol 2004; 24:407-419
38. Varinou L, Ramsauer K, Karaghiosoff M, et al. Phosphorylation of the Stat1 transactivation domain is required for full-fledged IFN-gamma-dependent innate immunity. Immunity 2003; 19:793-802
39. Friedbichler K, Kerenyi MA, Kovacic B, et al. Stat5a serine 725 and 779 phosphorylation is a prerequisite for hematopoietic transformation. Blood 2010; 116:1548-1558
40. Sadzak I, Schiff M, Gattermeier I, et al. Recruitment of Stat1 to chromatin is required for interferon-induced serine phosphorylation of Stat1 transactivation domain. Proc Natl Acad Sci U S A 2008; 105:8944-8949
41. Bancerek J, Poss ZC, Steinparzer I, et al. CDK8 kinase phosphorylates transcription factor STAT1 to selectively regulate the interferon response. Immunity 2013; 38:250-262
42. Yoshida H, Kotani H, Kondo T, et al. CDK inhibitors suppress Th17 and promote iTreg differentiation, and ameliorate experimental autoimmune encephalomyelitis in mice. Biochem Biophys Res Commun 2013; 435:378-384
43. Christofferson DE, Li Y, Hitomi J, et al. A novel role for RIP1 kinase in mediating TNFalpha production. Cell Death Dis 2012; 3:e320
44. Lukens JR, Vogel P, Johnson GR, et al. RIP1-driven autoinflammation targets IL-1alpha independently of inflammasomes and RIP3. Nature 2013; 498:224-227
45. Soond DR, Bjorgo E, Moltu K, et al. PI3K p110delta regulates T-cell cytokine production during primary and secondary immune responses in mice and humans. Blood 2010; 115:2203-2213
46. Durand CA, Richer MJ, Brenker K, et al. Selective pharmacological inhibition of phosphoinositide 3-kinase p110delta opposes the progression of autoimmune diabetes in nonobese diabetic (NOD) mice. Autoimmunity 2013; 46:62-73
47. Winkler DG, Faia KL, Dinitto JP, et al. PI3K-delta and PI3K-gamma inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. Chem Biol 2013; 20:1364-1374